Table 2.

Recommendations regarding some maintenance strategies post-transplant in ALL.

Disease	Agent	Recommendation
Ph-positive ALL	Tyrosine kinase inhibitors Imatinib Dasatinib Ponatinib	Recommended Encouraged Investigational
Ph-negative ALL	Blinatumumab Inotuzumab ozogamicin CAR T-cell therapy	Implemented by some transplant centers Investigational Investigational
T-cell ALL	HMA +/- venetoclax	Investigational